By Kashish Tandon (Reuters) -Shares of India's Glenmark Pharmaceuticals jumped 10% to a record high on Friday, a day after ...

Glenmark Pharmaceuticals Ltd.’s licensing pact with AbbVie Inc. for its blood cancer drug is boosting optimism over Indian ...

With a $2-billion cancer drug deal in its pocket, Glenmark’s licensing agreement with AbbVie not only unlocks a potential ...

Glenmark Pharmaceuticals shares rallied 10% on Friday to reach a record high after its biotech subsidiary signed a ...

Glenmark Pharma’s licensing pact for its investigational cancer drug ISB 2001 is not just a deal --it’s a turning point in ...

“With $2 billion in deal value and double-digit royalties, AbbVie’s implied peak sales estimate for this molecule is likely ...

AbbVie has placed a high price on that potential, coughing up $700 million for a phase 1 candidate and offering up to $1.225 ...

Glenmark Pharma's exclusive licensing deal with AbbVie for ISB-2001 could be transformative, offering significant upside ...

Yahoo Finance anchor Julie Hyman examines some of the top headlines on Wall Street on Thursday, July 10 in this episode of ...

Glenmark Pharmaceuticals' shares surged 10% to an all-time high of ₹2,094 following the announcement of an exclusive ...

The deal hands AbbVie a drug that’s shown early promise in multiple myeloma and may be useful treating other cancers and ...

The stock was the top percentage gainer on the Nifty Pharma index, which traded 0.3% higher compared to a 0.8% loss in the ...